Play all audios:
File this under “What was he thinking?” The otherwise staid Milken Institute summit on health care grew unexpectedly heated on Thursday when George Yancopoulos, the Regeneron Pharmaceuticals
president and chief scientific officer, drew boos from the crowd as he became cantankerous and talked over the panel moderator, who had expressed concern about access to high-priced
Alzheimer’s medicines. The memorable moment began when Bertha Coombs, a CNBC reporter who was leading the panel, asked about a “crisis” that may occur when the U.S. health care system
attempts to pay for such a drug. She pointed to controversy that erupted several years ago when a new pill that cured hepatitis C emerged, but its high-price tag strained public and private
health insurance programs. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS,
PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe